Seegene signs Covid-19 test supply agreement with Brazil

Molecular diagnostics company Seegene has signed an agreement with Brazil’s Ministry of Health to supply four million Covid-19 tests.

The company will provide its Covid-19 tests, along with associated consumables, to help respond to a rapid increase in influenza A and Covid-19 infections in Brazil.

According to Seegene, more than 280,000 daily Covid-19 cases have recently been reported in the country.

The company will provide its Allplex SARS-CoV-2/FluA/FluB/RSV PCR test, which has the ability to detect influenza A and B, Covid-19 and respiratory syncytial virus (RSV) in a single test.

Allplex is expected to be the optimized test for ‘twindemic’ in Brazil, as it can distinguish between influenza A and Covid-19 cases.

The multiplex real-time PCR test received approval from Health Canada under its interim order last month. It allows simultaneous amplification and differentiation of respiratory symptoms.

Content from our partners
How VOC analysis can revolutionize oncology
Solve problems with medical device coatings

Ho Yi, Seegene’s Director of Sales and Marketing, said, “Seegene is uniquely positioned to meet the growing global need for Covid-19 and influenza testing and we are fully prepared to provide inventory. worldwide to help countries around the world in their struggle for daily life. return.”

Last month, the company launched the Allplex SARS-CoV-2 rapid PCR test, designed to target the E, RdRP and N Covid-19 genes to detect the disease regardless of variant.

Optimized for mass testing, the test provides PCR results in 60 minutes and helps labs increase testing volume without additional instruments.

The launch comes in response to the rapid spread of the Omicron variant across the world.

Related companies

Comments are closed.